Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122511 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01122511 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 4 participants.
The verdict
NCT01122511, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration
Interventions
- BIOLOGICAL ranibizumab
- OTHER sham
- DRUG 700 ug dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01122511
The ClinicalTrials.gov registry entry for NCT01122511 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT01122511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01122511 about?
NCT01122511 is a clinical study titled "Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration". This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration
What is the current status of trial NCT01122511?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-08. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01122511?
The interventions under investigation include: ranibizumab (BIOLOGICAL), sham (OTHER), 700 ug dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01122511?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.